All lobbying filings

Splitoak Strategies LLC

Splitoak Strategies LLC filed a Q2 report for Alnylam Pharmaceuticals, Inc. on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Alnylam Pharmaceuticals, Inc. · Biopharmaceutical company

As filed: SPLITOAK STRATEGIES LLC for ALNYLAM PHARMACEUTICALS, INC.

All filings by Splitoak Strategies LLC · Everything Alnylam Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 2

SARAH KUEHL EGGE

Previously held: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction
AMY JENSEN

Previously held: 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness

Bills named in this filing 1

H.R. 1672
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.